Anti-CD52 Monoclonal Antibody ALLO-647 clinical trials
Also written ALLO-647.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses Anti-CD52 Monoclonal Antibody ALLO-647 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ALLO-647
- 4
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Allogene Therapeutics (4)
Studies
Open first, then newest update. How each study uses Anti-CD52 Monoclonal Antibody ALLO-647 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaActive, not recruitingPhase 1Allogene TherapeuticsNCT04696731Written as ALLO-647
- Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)Active, not recruitingPhase 1/2Allogene TherapeuticsNCT04416984Written as ALLO-647
- Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular LymphomaCompletedPhase 1Allogene TherapeuticsNCT03939026Written as ALLO-647
- Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaTerminatedPhase 1/2Allogene TherapeuticsNCT05000450Written as ALLO-647
Given beside what is tested · 2 — Anti-CD52 Monoclonal Antibody ALLO-647 is usual care or a partner of the new treatment
- Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)CompletedPhase 1Allogene TherapeuticsNCT04093596Written as ALLO-647
- Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyTerminatedPhase 2Allogene TherapeuticsNCT05714345Written as ALLO-647